ABBV
🛡️ AbbVie is a major pharmaceutical company with a strong presence in immunology, oncology, and neuroscience.
📈 The company has shown consistent revenue growth and maintains high operating margins.
💰 AbbVie offers an attractive dividend yield and has a history of increasing dividends annually.
💼 Its acquisition of Allergan strengthened its position in the anti-aging market, particularly with aesthetic treatments.
@rankia:
“AbbVie is one of the largest pharmaceutical companies in the world, having separated from Abbott Laboratories in 2013. It specializes in innovative medicines in immunology, oncology, and neuroscience, and has established itself as a key player in the biopharma industry, operating in over 175 countries. In 2020, it acquired Allergan, strengthening its presence in the anti-aging niche, especially with aesthetic treatments involving neurotoxins and dermal fillers. Financially, AbbVie has shown solid growth, with consistent revenue expansion, operating margins above 40%, and normalized earnings per share close to $10. It generates a stable free cash flow of around $23 billion over the last three years, allowing it to increase investments in R&D while maintaining attractive shareholder return policies. AbbVie is known for its dividends, currently offering a dividend yield of 3.5% and has consistently increased them at a rate of 4-5% annually.”
Watch the exact part of the video where Rankia talks about AbbVie here:
Watch the video on YouTube.
Read more articles by the world’s top 100 analysts on AbbVie (ABBV) at the following link. ABBV stock.
